Autolus (AUTL) Q2 2026 Earnings Call Transcript
Autolus (AUTL) reported Q2 2026 net product revenue of $45.7M, up 119% YoY, and raised full-year guidance to $140M-$150M. Gross margin improved to 55%, and cash runway extends into Q2 2028. The company expanded treatment centers and saw initial U.K. sales.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY 2026 revenue guidance, the gross margin step-up, and the explicit funding runway extension via the Perceptive credit facility plus milestone-based tranches.
Market read
Traders can update valuation assumptions around growth rate, gross margin trajectory, and balance-sheet risk after the guidance raise and cash runway extension.
What to watch
R&D and SG&A are rising (R&D $27.9M, SG&A $41.2M), and the pipeline catalysts (BOBCAT, CATULUS, ALARIC) are still dated into 2027-2028, leaving near-term upside dependent on continued center activation and demand.
Background
Autolus held its Q2 2026 financial results conference call, covering commercial performance of AUCATZYL and updates across its clinical pipeline and financing.
Ticker impact
Autolus raised FY 2026 guidance to $140M-$150M and reported Q2 net product revenue of $45.7M, plus gross margin expansion to 55%.
Likely positive bias for the stock into the next few sessions as traders reprice growth and margin inflection, tempered by ongoing commercialization and clinical spend.
The call includes multiple decision-relevant datapoints: raised revenue guidance, a step-change in gross margin, and explicit cash runway into 2Q28 supported by a credit facility and milestone-based tranches.
Market effects
Supports the broader CAR-T commercialization narrative by highlighting center expansion, manufacturing fixed-cost absorption, and margin progression.
UK launch traction is early but provides a measurable international expansion datapoint for investors tracking US-to-UK scaling.
Reinforces investor appetite for cell therapy names with improving unit economics and extended funding runway.
Counterpoint
Margin improvement may be partly volume-driven and could reverse if manufacturing automation or batch economics do not deliver as planned.
Key entities
- companyAutolus Therapeutics
Subject of the earnings call, reporting Q2 results, raised FY 2026 guidance, margin expansion, and financing/cash runway details.
- productAUCATZYL (obe-cel)
Autolus' CD19-targeting CAR T therapy, driving net product revenue growth and center expansion.
- financingPerceptive Advisors credit facility
Up to $250M aggregate principal with an initial $75M drawn and additional tranches tied to revenue milestones.
